MedTrace Logo

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

NCT03806049 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2021-07-15

No results posted yet for this study

Summary

ENGOT-OV42 / NSGO-AVATAR: This three-arm randomized trial is to demonstrate efficacy of niraparib-bevacizumab-dostarlimab triplet combination against standard of care treatment and to demonstrate efficacy of niraparib-bevacizumab-dostarlimab triplet combination against niraparib-bevacizumab doublet combination for patients with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer

Conditions

Interventions

DRUG

Niraparib

given orally once daily

DRUG

Bevacizumab

given as iv infusion every three weeks

DRUG

TSR042

Given as IV infusion every three weeks

DRUG

Carboplatin

given as iv infusion every three weeks

DRUG

Paclitaxel

given as iv infusion every three weeks

Sponsors & Collaborators

  • Nordic Society of Gynaecological Oncology - Clinical Trials Unit

    lead OTHER

Principal Investigators

  • MANSOOR RAZA R MIRZA · NSGO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-31
Primary Completion
2022-12-31
Completion
2024-12-31

Countries

  • Denmark
  • Finland
  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03806049 on ClinicalTrials.gov